Additionally, up-regulated PRMT1 repressed E-cadherin activity and promoted EMT in erlotinib-resistant NSCLC cells (erlotinib is a tyrosine kinase inhibitor against NSCLC) [135]. Here, CDH1 is linked to non-small cell lung carcinoma.